Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Assembly Biosciences Inc. | AB-729, ATI-2173 and Viread (tenofovir disoproxil fumarate) - (SAVE-1) | Hepatitis B | Phase 2a | Ongoing | AB-729 subcutaneous ATI-2173 oral Viread oral | Antiviral |
| Assembly Biosciences Inc. | VEN 307 (diltiazem cream) | Anal fissures | Phase 3 | Trial Discontinued | Topical | Gastroenterology |
| Astellas Pharma Inc. ADR | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) | Muscle-invasive bladder cancer (MIBC) | PDUFA | Data Released | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) | Muscle-invasive bladder cancer (MIBC) | PDUFA | Data Released | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | Zolbetuximab + CAPOX - (GLOW) | Claudin-18 isoform 2-positive (CLDN18.2)+, HER2‚àí, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
| Astellas Pharma Inc. ADR | Fezolinetant - (DAYLIGHT) | Severe vasomotor symptoms (VMS) due to menopause | Phase 3 | Data Released | Oral | Women's Health |
| Astellas Pharma Inc. ADR | Fezolinetant - (STARLIGHT 2) | Vasomotor symptoms (VMS) | Phase 3 | Enrollment Initiation | Oral | Women's Health |
| Astellas Pharma Inc. ADR | Avacincaptad pegol (Zimura) | Wet age-related macular degeneration (Wet-AMD) | Phase 2a | Intravitreal injection | Opthalmic |
